In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to a new study.

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be diagnosed with Alzheimer’s disease compared with people on other diabetes medications.

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.

Hims & Hers Health will have a commercial air during Super Bowl LIX. It’s already courting controversy, with calls to bar the game’s host, Fox, from broadcasting it. Why? Experts and advocates in the health care space are saying that the 60-second spot — which deems obesity “America’s deadliest epidemic,

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.